Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Parkinson’s disease (PD) is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopami...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecht, Shimon, Haroutiunian, Simon, Hoffman, Amnon, Lazarovici, Philip
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386362/
https://www.ncbi.nlm.nih.gov/pubmed/18488080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386362/
https://www.ncbi.nlm.nih.gov/pubmed/18488080

Ejemplares similares